BACKGROUND: Epidemiologic data on serum melatonin, a marker of circadian rhythms, and cancer are sparse due largely to the lack of reliable assays with high sensitivity to detect relatively low melatonin levels in serum collected during daylight, as commonly available in most epidemiologic studies. METHODS: To help expand epidemiologic research on melatonin, we assessed the reproducibility and refined a currently available melatonin RIA, and evaluated its application to epidemiologic investigations by characterizing melatonin levels in serum, urine, and/or plasma in 135 men from several ethnic groups. RESULTS: Reproducibility was high for the standard 1.0-mL serum [mean coefficient of variation (CV), 6.9%; intraclass correlation coefficient (ICC), 97.4%; n = 2 serum pools in triplicate] and urine-based (mean CV, 3.5%; ICC, 99.9%) assays. Reproducibility for the 0.5-mL refined-serum assay was equally good (mean CV, 6.6%; ICC, 99.0%). There was a positive correlation between morning serum melatonin and 6-sulfatoxymelatonin in 24-hour urine (r = 0.46; P = 0.008; n = 49 subjects). Melatonin levels in serum-plasma pairs had a high correlation (r = 0.97; P < 1x10(-4); n = 20 pairs). Morning serum melatonin levels were five times higher than those from the afternoon (before 9 a.m. mean, 11.0 pg/mL, versus after 11 a.m. mean, 2.0 pg/mL). Chinese men had lower melatonin levels (mean, 3.4 pg/mL), whereas Caucasian, African-American, and Ghanaian men had similar levels (mean, 6.7-8.6 pg/mL). CONCLUSIONS: These results suggest that melatonin can be detected reliably in serum samples collected in epidemiologic studies in various racial groups. IMPACT: With improved assays, it may be possible to investigate the role of melatonin and the emerging circadian rhythm hypothesis in cancer etiology in epidemiologic studies.
BACKGROUND: Epidemiologic data on serum melatonin, a marker of circadian rhythms, and cancer are sparse due largely to the lack of reliable assays with high sensitivity to detect relatively low melatonin levels in serum collected during daylight, as commonly available in most epidemiologic studies. METHODS: To help expand epidemiologic research on melatonin, we assessed the reproducibility and refined a currently available melatonin RIA, and evaluated its application to epidemiologic investigations by characterizing melatonin levels in serum, urine, and/or plasma in 135 men from several ethnic groups. RESULTS: Reproducibility was high for the standard 1.0-mL serum [mean coefficient of variation (CV), 6.9%; intraclass correlation coefficient (ICC), 97.4%; n = 2 serum pools in triplicate] and urine-based (mean CV, 3.5%; ICC, 99.9%) assays. Reproducibility for the 0.5-mL refined-serum assay was equally good (mean CV, 6.6%; ICC, 99.0%). There was a positive correlation between morning serum melatonin and 6-sulfatoxymelatonin in 24-hour urine (r = 0.46; P = 0.008; n = 49 subjects). Melatonin levels in serum-plasma pairs had a high correlation (r = 0.97; P < 1x10(-4); n = 20 pairs). Morning serum melatonin levels were five times higher than those from the afternoon (before 9 a.m. mean, 11.0 pg/mL, versus after 11 a.m. mean, 2.0 pg/mL). Chinese men had lower melatonin levels (mean, 3.4 pg/mL), whereas Caucasian, African-American, and Ghanaian men had similar levels (mean, 6.7-8.6 pg/mL). CONCLUSIONS: These results suggest that melatonin can be detected reliably in serum samples collected in epidemiologic studies in various racial groups. IMPACT: With improved assays, it may be possible to investigate the role of melatonin and the emerging circadian rhythm hypothesis in cancer etiology in epidemiologic studies.
Authors: L W Chu; Y Zhu; K Yu; T Zheng; H Yu; Y Zhang; I Sesterhenn; A P Chokkalingam; K N Danforth; M-C Shen; F Z Stanczyk; Y-T Gao; A W Hsing Journal: Prostate Cancer Prostatic Dis Date: 2007-11-06 Impact factor: 5.554
Authors: Yong Zhu; Richard G Stevens; Derek Leaderer; Aaron Hoffman; Theodore Holford; Yawei Zhang; Heather N Brown; Tongzhang Zheng Journal: Breast Cancer Res Treat Date: 2007-04-24 Impact factor: 4.872
Authors: Aaron E Hoffman; Tongzhang Zheng; Richard G Stevens; Yue Ba; Yawei Zhang; Derek Leaderer; Chunhui Yi; Theodore R Holford; Yong Zhu Journal: Cancer Res Date: 2009-03-24 Impact factor: 12.701
Authors: M Kakizaki; S Kuriyama; T Sone; K Ohmori-Matsuda; A Hozawa; N Nakaya; S Fukudo; I Tsuji Journal: Br J Cancer Date: 2008-09-23 Impact factor: 7.640
Authors: Denise M Ney; Sangita G Murali; Bridget M Stroup; Nivedita Nair; Emily A Sawin; Fran Rohr; Harvey L Levy Journal: Mol Genet Metab Date: 2017-04-06 Impact factor: 4.797
Authors: Xiao-Si Wang; Sarah Tipper; Paul N Appleby; Naomi E Allen; Timothy J Key; Ruth C Travis Journal: Am J Epidemiol Date: 2014-01-12 Impact factor: 4.897
Authors: Stephane Fournier; Patrick Taffé; Dragana Radovanovic; Erik Von Elm; Beata Morawiec; Jean-Christophe Stauffer; Paul Erne; Ahmed Beggah; Pierre Monney; Patrizio Pascale; Juan-Fernando Iglesias; Eric Eeckhout; Olivier Muller Journal: PLoS One Date: 2015-03-11 Impact factor: 3.240